 | |
| Clinical data | |
|---|---|
| Trade names | Amitiza, others |
| Other names | RU-0211 SPI-0211 |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a607034 |
| License data |
|
| Routes of administration | By mouth |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | Negligible |
| Protein binding | 94% |
| Metabolism | Extensive, CYP not involved |
| Elimination half-life | Unknown (lubiprostone) 0.9–1.4 hours (main metabolite) |
| Excretion | Kidney (60%) and fecal (30%) |
| Identifiers | |
| |
| Chemical and physical data | |
| Formula | C20H32F2O5 |
| Molar mass | 390.468 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Lubiprostone, sold under the trade name Amitiza among others, is a medication used to treat chronic constipation of unknown cause and irritable bowel syndrome associated constipation.[1] It is taken by mouth.[1]
Common side effects include nausea, diarrhea, abdominal pain, swelling, and tiredness.[1] Other side effects may include shortness of breath.[1] Safety in pregnancy is unclear.[1] It works by activating certain chloride channels in the intestines which increases fluid release.[1]
Lubiprostone was approved for medical use in the United States in 2006 and Canada in 2015.[1][2] In the United States a month of medication costs about 290 USD as of 2021.[3] A generic version was approved in 2021 in the USA.[4] It is not commercially available in the United Kingdom.[5]
References edit
- ^ a b c d e f g h i j "Lubiprostone Monograph for Professionals". Drugs.com. Archived from the original on 22 September 2020. Retrieved 24 November 2021.
- ^ "Health Canada New Drug Authorizations: 2015 Highlights". Health Canada. 2016-05-04. Archived from the original on 2020-02-20. Retrieved 2020-02-20.
- ^ "Lubiprostone". Archived from the original on 31 August 2016. Retrieved 24 November 2021.
- ^ Research, Center for Drug Evaluation and (10 February 2022). "2021 First Generic Drug Approvals". FDA. Archived from the original on 21 June 2022. Retrieved 22 October 2022.
- ^ "Lubiprostone for treating chronic idiopathic constipation | Guidance | NICE". www.nice.org.uk. Archived from the original on 18 June 2021. Retrieved 24 November 2021.